Use of perlecan domain V in treating amyloidogenic disease

Thumbnail
View/Open
Date
2016-06-07
Author
Metadata
Show full item record
Abstract
The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
URI
http://hdl.handle.net/1969.1/177150
Subject
1/1
Collections
Citation
Bix, Gregory J.; Wright, Sarah; Griswold-prenner, Irene (2016). Use of perlecan domain V in treating amyloidogenic disease. United States. Patent and Trademark Office; Texas A&M University. Libraries. Available electronically from http : / /hdl .handle .net /1969 .1 /177150.